Screening, consent, monitoring and follow-up without blanket safety or pain-free claims.
Quick answer
Intravenous cell administration starts with physician assessment of product and route suitability, followed by required tests, informed consent, product verification and monitoring during and after administration. Protocols differ and not every product is suitable for IV use. Khun Kim coordinates questions and appointments, not medical decisions.
The clinician reviews goals, diagnoses, allergies, current treatment and product evidence. Arriving at a clinic does not establish eligibility. Additional information or another approach may be needed; screening supports individual care.
Before consent, understand the product, cell source, route, expected benefits, limitations, alternatives and relevant risks. Allow time for questions and interpretation. Khun Kim may coordinate language support; medical explanation and consent remain with clinician and patient.
The clinical team follows identity and product checks and monitors according to its protocol. Report symptoms promptly. This article does not prescribe infusion rate, duration or dose; those depend on the product and physician plan.
The supplied image shows care at a treatment bed, but does not verify the substance administered or any outcome. The patient’s face is obscured and the image is contextual only. IV care is not described as risk-free or pain-free for everyone.
Request aftercare instructions, a summary, clinic contact and feasible follow-up after returning home. Continue prescribed care unless your doctor changes it, and coordinate with your home clinician where needed. Khun Kim assists communication; emergencies require immediate medical care.
Share your goal, history and recent tests privately through the channel provided by the team for physician review. Include eGFR, creatinine and UACR if relevant and available. Do not post medical records in public comments.
Contact Khun KimCare setting with patient face obscured; the product is not verified from the photograph · Owner-supplied image; not verification of product identity, licensing or outcomes
No. The specific product and route must be clinically assessed and fit the applicable pathway.
Needle discomfort and product or procedure risks are possible; discuss them before consent.
It depends on screening, product, administration and observation; confirm with the treating team.
5 points • reviewed 2026-11-14
Reviewed and last updated: 2026-11-14
10 sources • every claim is traceable
https://www.ehlbio.co.kr/company/about/
https://www.ehlbio.co.kr/rd/gmp/
https://www.ehlbio.co.kr/company/contact/
https://mohw.go.kr/board.es?act=view&bid=0027&list_no=1483481&mid=a10503000000
https://www.mohw.go.kr/board.es?act=view&bid=0026&list_no=1487217&mid=a10409020000
https://www.ehlbio.co.kr/company/history/
https://www.ehlbio.co.kr/rd/institute/
https://www.ehlbio.co.kr/rd/patent/
https://www.ehlbio.co.kr/conditioned/
https://www.ehlbio.co.kr/immune_cell/
Last updated: 2026-11-14 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categories